Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics

Abstract

Biosimilars provide safety, purity, and potency similar to those of a reference biologic product. An array of protein analytical techniques was used to compare the physicochemical properties of proposed biosimilar filgrastim (EP2006), US-approved originator filgrastim, and EU-approved originator filgrastim. Biological characterization involved surface… (More)
DOI: 10.1007/s40259-015-0124-7

Topics

6 Figures and Tables

Statistics

010020020162017
Citations per Year

Citation Velocity: 49

Averaging 49 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@inproceedings{Soergel2015ComparabilityOB, title={Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics}, author={Fritz Soergel and Arnd Schwebig and Johann Holzmann and Stefan J Prasch and Pritibha Singh and Martina Kinzig}, booktitle={BioDrugs}, year={2015} }